Quidel

(QDEL) Quidel Corp.

Last updated:

April 13, 2022 at 11.07am

Company Overview:

A major American manufacturer of diagnostic healthcare products, cellular-based virology assays and molecular diagnostic testing solutions sold worldwide, Quidel Corp develops, manufactures and markets diagnostic testing solutions for applications in infectious, diseases, cardiology, thyroid, general health, eye health, gastrointestinal diseases and toxicology. The company’s Sofia 2 SARS Antigen FIA became the first COVID-19 antigen test to be granted Emergency Use Authorisation (EUA) by the FDA (Food and Drug Administration). These diagnostic tests are known to quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.  
 
Quidel provides diagnostic testing solutions under a number of brands, namely Quidel, QuickVue, QuickVue+, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Amplivue, Lyra and Thyretain, while its products are marketed through its distributors and direct sales force for use in doctors’ offices, hospital, clinical laboratories, universities, as well as pharmacies and wellness screening centres.